Myotonic Dystrophy 2 (DM2) Cell Models for Research

Myotonic Dystrophy 2 (DM2) is a rare autosomal dominant disorder with an estimated prevalence of 1 in 100,000 to 1 in 10,000 depending on population (WHO, 2023). It is characterized by progressive muscle weakness, myotonia, cataracts, cardiac conduction defects, and insulin resistance. The disease typically manifests in adulthood, with a variable phenotype that often leads to underdiagnosis. There is no cure, and current treatments are symptomatic. The clinical burden is significant, with a reduced quality of life and increased morbidity.

DM2 is an excellent model for studying RNA-mediated toxicity and spliceopathy, as it is caused by a CCTG repeat expansion in the CNBP gene (also known as ZNF9). This expansion leads to the accumulation of toxic RNA foci that sequester RNA-binding proteins, disrupting alternative splicing. DM2 provides a unique opportunity to investigate the molecular mechanisms of microsatellite repeat disorders and to develop therapeutic strategies targeting RNA toxicity. Public datasets, such as those from the NIH and NCBI, provide valuable resources for studying the disease.

The primary pathogenic mechanism in DM2 is the toxic gain-of-function of the expanded CCTG repeat RNA. This leads to:

• • Sequestration of Muscleblind-like (MBNL) proteins, particularly MBNL1 and MBNL2, by the repeat RNA.
• • Dysregulation of CELF (CUGBP, Elav-like family) proteins, leading to altered splicing.
• • Disruption of alternative splicing of multiple genes, including CLCN1, INSR, and TNNT2, contributing to myotonia, insulin resistance, and muscle weakness.
• • Activation of the PKC pathway and other signaling cascades that exacerbate the phenotype.

Data from NCBI Gene and ClinVar.

DM2 affects multiple signaling networks:

• • RNA splicing network: MBNL and CELF proteins regulate alternative splicing of hundreds of genes. Their dysregulation leads to global splicing changes.
• • Insulin signaling: Altered splicing of INSR results in reduced insulin receptor activity, contributing to insulin resistance.
• • Muscle function: CLCN1 splicing changes reduce chloride channel activity, causing myotonia.
• • Calcium signaling: Dysregulation of calcium handling proteins, such as SERCA, may contribute to muscle weakness.

Organoids derived from patient iPSCs are also emerging as powerful models to study muscle and neuronal phenotypes in a 3D context.

• • Transgenic mouse models: Express expanded CCTG repeats in the context of the human CNBP gene, recapitulating RNA foci and splicing defects.
• • Knock-in mouse models: Insert expanded repeats into the mouse Ccnb1 locus.
• • Drosophila models: Express expanded repeats to study RNA toxicity in a simpler system.
• • Zebrafish models: Used for rapid screening of therapeutic agents.

Patient-derived xenografts (PDX) are not commonly used for DM2 due to the non-cancerous nature of the disease.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise modifications in the CNBP gene. For example:

• • CNBP knockout cell lines: Generated by introducing frameshift mutations, leading to loss of CNBP protein. These models help study the loss-of-function effects, although DM2 is primarily a gain-of-function disease.
• • Knock-in cell lines with expanded CCTG repeats: Introduce a pathogenic repeat expansion into the endogenous CNBP locus, recapitulating the toxic RNA phenotype.
• • Reporter cell lines: Engineered to express fluorescent proteins under the control of splicing reporters, allowing high-throughput screening of splicing modulators.

These gene-edited models are commercially available and sequence-verified, providing reliable tools for drug discovery and functional genomics.

Gene-edited cell lines are essential for validating the role of CNBP and other genes in DM2 pathogenesis. For example:

• • Knockout of MBNL1 in muscle cells can mimic the splicing defects seen in DM2, allowing the study of downstream effects.
• • Knock-in of expanded repeats enables the identification of genes whose expression is altered by RNA toxicity.
• • CRISPR screens using knockout libraries can identify modifiers of the DM2 phenotype, such as genes that rescue splicing defects.

Isogenic pairs (e.g., wild-type vs. repeat-expanded) are powerful for drug screening. They allow the identification of compounds that specifically reverse the DM2-associated splicing changes. Additionally, gene-edited models can be used to test resistance mechanisms to antisense oligonucleotides or small molecules targeting the repeat RNA.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of the DM2 mutation. These genes may serve as novel therapeutic targets. Additionally, gene-edited models can be used to discover biomarkers for disease progression or response to therapy.